The closing price of Outlook Therapeutics Inc (NASDAQ: OTLK) was $0.42 for the day, up 4.01% from the previous closing price of $0.41. In other words, the price has increased by $+0.0163 from its previous closing price. On the day, 993972 shares were traded.
Ratios:
Our analysis of OTLK’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 0.44 and its Current Ratio is at 0.44.
CapitalOne Upgraded its Equal Weight to Overweight on December 27, 2023, while the target price for the stock was maintained at $5.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Apr 20 when Dagnon Terry sold 520,000 shares for $1.14 per share. The transaction valued at 590,200 led to the insider holds 653,058 shares of the business.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, OTLK now has a Market Capitalization of 106.26M and an Enterprise Value of 132.45M. Its current Enterprise Value per Revenue stands at 23.71 whereas that against EBITDA is -2.55.
Stock Price History:
Over the past 52 weeks, OTLK has reached a high of $2.03, while it has fallen to a 52-week low of $0.20. The 50-Day Moving Average of the stock is 0.4095, while the 200-Day Moving Average is calculated to be 0.8238.
Shares Statistics:
OTLK traded an average of 2.00M shares per day over the past three months and 1.3M shares per day over the past ten days. A total of 260.26M shares are outstanding, with a floating share count of 147.51M. Insiders hold about 43.32% of the company’s shares, while institutions hold 11.49% stake in the company. Shares short for OTLK as of Feb 15, 2024 were 13.2M with a Short Ratio of 6.59, compared to 12.13M on Jan 12, 2024. Therefore, it implies a Short% of Shares Outstanding of 5.07% and a Short% of Float of 7.13%.
Earnings Estimates
The firm’s stock currently is rated by 5 analysts. On average, analysts expect EPS of -$0.05 for the current quarter, with a high estimate of -$0.03 and a low estimate of -$0.06, while EPS last year was -$0.03. The consensus estimate for the next quarter is -$0.05, with high estimates of -$0.03 and low estimates of -$0.08.
Analysts are recommending an EPS of between -$0.14 and -$0.25 for the fiscal current year, implying an average EPS of -$0.19. EPS for the following year is -$0.14, with 5 analysts recommending between -$0.05 and -$0.29.
